Atherosclerotic Cardiovascular Disease (ASCVD) research hub
4 indexed studies · 2 currently recruiting
- active not recruitingPHASE3
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
This study looks at a new drug, lepodisiran, to help people with high lipoprotein(a) reduce their risk of heart attacks and strokes. It's for adults with existing heart disease or those at high risk. The drug is given as an injection under the skin.
United States · Argentina · Australia - active not recruitingPHASE3
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
This study looks at whether a new medicine, retatrutide, can help adults with obesity who also have heart disease or kidney problems. It aims to see if the medicine can reduce serious heart issues or stop kidney problems from getting worse.
United States · Argentina · Australia - recruitingPHASE3
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
This study looks at a new medicine, pelacarsen, for people with heart and circulation problems and high levels of a specific fat called Lp(a). It aims to see if it's safe and effective when used alongside another medicine, inclisiran.
United States · China · France - recruitingPHASE3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
This study looks at a new medicine called muvalaplin to see if it can lower the risk of heart attacks and strokes in people with high levels of a specific fat in their blood called Lp(a).
United States · Argentina · Australia